This Biotech's Run Is Far From Done

By Dave Williamson – Mar 5, 2013 at 5:48PM

NASDAQ: GILD

Gilead Sciences

Market Cap

$83B

Today's Change

(-0.56%) -$0.38

Current Price

$66.93

Price as of April 17, 2024, 4:00 p.m. ET

Two pieces of news that show Gilead still has plenty of room to run.

In the following video, Motley Fool health-care analyst David Williamson looks at two major pieces of news surrounding biotech company Gilead (GILD -0.56%) that show that the company has a bright future ahead. He discusses another 100% cure rate for the company in the hepatitis-C space, and a new once-daily HIV drug for the company, with a better safety profile than the competition.

David Williamson has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Johnson & Johnson and owns shares of Johnson & Johnson. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.